DENVER, March 11, 2002 ? Qwest Communications International Inc. (NYSE: Q), the broadband communications company, today announced that it has extended its multi-year agreement with pharmaceutical giant AstraZeneca (NYSE:AZN), by providing the first-of-its-kind interactive television commercial. Qwest provides AstraZeneca a variety of communications services including Web site design, interactive advertising, and Internet strategic consulting.

The newest technology deployment is a television commercial that allows consumers with interactive TV capabilities to order information about ZOMIG®(zolmitriptan)*, an AstraZeneca migraine medicine, directly through their televisions. Also, Qwest designed, maintains and provides Internet Advertising for the Web site, among many other AstraZeneca sites.

?Qwest has been an excellent communications partner for several years because it provides the type of tailored service and innovative ideas that help enhance our business,? said Kristin Williamson, AstraZeneca E-Promotions Manager ?The interactive television commercial for ZOMIG is an example of how Qwest?s expertise have helped ZOMIG achieve its business objectives.?

?AstraZeneca is using technology the right way by developing new applications, such as this new interactive TV commercial, to help drive awareness,? said Shaun Gilmore, executive vice president, Qwest Global Accounts. ?We?re pleased to have such a strong partnership with AstraZeneca, and to continue working with leading businesses in the medical and pharmaceutical industries ? key growth areas in 2002.?

About Qwest

Qwest Communications International Inc. (NYSE: Q) is a leader in reliable, scalable and secure broadband data, voice and image communications for businesses and consumers. The Qwest Macro Capacity® Fiber Network, designed with the newest optical networking equipment for speed and efficiency, spans more than 190,000 miles globally. For more information, please visit the Qwest Web site at

About AstraZeneca

AstraZeneca (NYSE:AZN) is a major international healthcare business engaged in the research, development, manufacture and marketing of ethical (prescription) pharmaceuticals and the supply of healthcare services. It is one of the top five pharmaceutical companies in the world with healthcare sales of $16.4 billion and leading positions in sales of gastrointestinal, oncology, anesthesia (including pain management), cardiovascular, central nervous system (CNS) and respiratory products. In the United States, AstraZeneca is an $8.7 billion healthcare business with more than 10,000 employees.

*ZOMIG®(zolmitriptan) is a registered trademark of AstraZeneca.

This release may contain projections and other forward-looking statements that involve risks and uncertainties. These statements may differ materially from actual future events or results. Readers are referred to the documents filed by Qwest Communications International Inc. (together with its affiliates, ?Qwest?, ?we? or ?us?) with the Securities and Exchange Commission, specifically the most recent reports which identify important risk factors that could cause actual results to differ from those contained in the forward-looking statements, including but not limited to: potential fluctuations in quarterly results; volatility of Qwest?s stock price; intense competition in the markets in which we compete; changes in demand for our products and services; the duration and extent of the current economic downturn, including its effect on our customers and suppliers; adverse economic conditions in the markets served by us or by companies in which we have substantial investments; dependence on new product development and acceleration of the deployment of advanced new services, such as broadband data, wireless and video services, which could require substantial expenditure of financial and other resources in excess of contemplated levels; higher than anticipated employee levels, capital expenditures and operating expenses; rapid and significant changes in technology and markets; adverse changes in the regulatory or legislative environment affecting our business, delays in our ability to provide interLATA services within our 14-state local service area; failure to maintain rights-of-way; and failure to achieve the projected synergies and financial results expected to result from the acquisition of U S WEST, and difficulties in combining the operations of the combined company. This release may include analysts? estimates and other information prepared by third parties for which we assume no responsibility. We undertake no obligation to review or confirm analysts? expectations or estimates or to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

The Qwest logo is a registered trademark of, and CyberCenter is a service mark of, Qwest Communications International Inc. in the U.S. and certain other countries.

Contact Information
Media Contact
Claire Mylott
Investor Contact
Lee Wolfe
(800) 567-7296